The efficacy of astegolimab, a human IgG2 monoclonal antibody directed against ST2, was assessed for the treatment of severe asthma in a phase 2b, randomized, placebo-controlled, double-blind clinical trial in which thirty-six percent of the patients had a BMI greater than 30 kg/m2 [89]. Here, IL1RL1 is linked to asthma.